Micro cell vesicle technology (mCVT): a novel hybrid system of gene delivery for hard-to-transfect (HTT) cells.,Nanoscale

当前位置： X-MOL 学术 › Nanoscale › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Micro cell vesicle technology (mCVT): a novel hybrid system of gene delivery for hard-to-transfect (HTT) cells.
Nanoscale ( IF 5.8 ) Pub Date : 2020-08-18 , DOI: 10.1039/d0nr03784b
Yi-Hsuan Ou ₁ , Shui Zou , Wei Jiang Goh , Suet Yen Chong , Gopalakrishnan Venkatesan , Matthias G Wacker , Gerrit Storm , Jiong-Wei Wang , Bertrand Czarny , Giorgia Pastorin , Esther C Y Woon

Affiliation

A hybrid gene delivery platform, micro Cell Vesicle Technology (mCVT), produced from the fusion of plasma membranes and cationic lipids, is presently used to improve the transfection efficiency of hard-to-transfect (HTT) cells. The plasma membrane components of mCVTs impart specificity in cellular uptake and reduce cytotoxicity in the transfection process, while the cationic lipids complex with the genetic material and provide structural integrity to mCVTs.

中文翻译：

微细胞囊泡技术（mCVT）：一种用于难以转染（HTT）细胞的新型基因传递混合系统。

由质膜和阳离子脂质的融合产生的杂交基因递送平台，微细胞囊泡技术（mCVT），目前用于改善难转染（HTT）细胞的转染效率。mCVT的质膜成分赋予细胞摄取特异性，并在转染过程中降低细胞毒性，而阳离子脂质与遗传物质复合并为mCVT提供结构完整性。

更新日期：2020-09-18

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11